Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 6
2014 5
2015 2
2016 2
2017 3
2018 3
2019 1
2020 3
2021 5
2022 7
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
BRAF inhibitors in cancer therapy.
Hertzman Johansson C, Egyhazi Brage S. Hertzman Johansson C, et al. Among authors: egyhazi brage s. Pharmacol Ther. 2014 May;142(2):176-82. doi: 10.1016/j.pharmthera.2013.11.011. Epub 2013 Dec 8. Pharmacol Ther. 2014. PMID: 24325952 Review.
Novel loss-of-function variant in DENND5A impedes melanosomal cargo transport and predisposes to familial cutaneous melanoma.
Yang M, Johnsson P, Bräutigam L, Yang XR, Thrane K, Gao J, Tobin NP, Zhou Y, Yu R, Nagy N, Engström PG, Tuominen R, Eriksson H, Lundeberg J, Tucker MA, Goldstein AM, Egyhazi-Brage S, Zhao J, Cao Y, Höiom V. Yang M, et al. Among authors: egyhazi brage s. Genet Med. 2022 Jan;24(1):157-169. doi: 10.1016/j.gim.2021.09.003. Epub 2021 Nov 30. Genet Med. 2022. PMID: 34906508 Free PMC article.
Immune gene expression and response to chemotherapy in advanced breast cancer.
Foukakis T, Lövrot J, Matikas A, Zerdes I, Lorent J, Tobin N, Suzuki C, Brage SE, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Fernö M, Skoog L, Bergh J, Hatschek T. Foukakis T, et al. Among authors: brage se. Br J Cancer. 2018 Feb 20;118(4):480-488. doi: 10.1038/bjc.2017.446. Epub 2018 Jan 25. Br J Cancer. 2018. PMID: 29370583 Free PMC article. Clinical Trial.
Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors.
Azimi A, Caramuta S, Seashore-Ludlow B, Boström J, Robinson JL, Edfors F, Tuominen R, Kemper K, Krijgsman O, Peeper DS, Nielsen J, Hansson J, Egyhazi Brage S, Altun M, Uhlen M, Maddalo G. Azimi A, et al. Among authors: egyhazi brage s. Mol Syst Biol. 2018 Mar 5;14(3):e7858. doi: 10.15252/msb.20177858. Mol Syst Biol. 2018. PMID: 29507054 Free PMC article.
Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib.
Vidarsdottir L, Fernandes RV, Zachariadis V, Das I, Edsbäcker E, Sigvaldadottir I, Azimi A, Höiom V, Hansson J, Grandér D, Egyházi Brage S, Pokrovskaja Tamm K. Vidarsdottir L, et al. Among authors: egyhazi brage s. Melanoma Res. 2020 Oct;30(5):443-454. doi: 10.1097/CMR.0000000000000675. Melanoma Res. 2020. PMID: 32467529 Free PMC article.
Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial.
Backlund E, Yang M, Grozman V, Masucci G, Falkenius J, Eriksson H, Jovanovic B, Hammarlund K, Isacsson U, Radu C, Abel E, Karlsson K, Palanco Zamora R, Wersäll P, Edbäck U, Wickström S, Darai Ramqvist E, Egyhazi Brage S, Kiessling R, Viktorsson K, Franzén B, Lewensohn R, Olofsson Bagge R, Ullenhag GJ, Ny L, Lindberg K, Helgadottir H. Backlund E, et al. Among authors: egyhazi brage s. Acta Oncol. 2022 Jul;61(7):869-873. doi: 10.1080/0284186X.2022.2079959. Epub 2022 May 31. Acta Oncol. 2022. PMID: 35638255 No abstract available.
31 results